• This record comes from PubMed

Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy: A Randomized Controlled Trial

. 2024 Mar 12 ; 102 (5) : e208112. [epub] 20240209

Language English Country United States Media print-electronic

Document type Randomized Controlled Trial, Journal Article

Grant support
EP-C-15-004 EPA - United States CEP Register

BACKGROUND AND OBJECTIVES: Vamorolone is a dissociative agonist of the glucocorticoid receptor that has shown similar efficacy and reduced safety concerns in comparison with prednisone in Duchenne muscular dystrophy (DMD). This study was conducted to determine the efficacy and safety of vamorolone over 48 weeks and to study crossover participants (prednisone to vamorolone; placebo to vamorolone). METHODS: A randomized, double-blind, placebo-controlled and prednisone-controlled clinical trial of 2 doses of vamorolone was conducted in participants with DMD, in the ages from 4 years to younger than 7 years at baseline. The interventions were 2 mg/kg/d of vamorolone and 6 mg/kg/d of vamorolone for 48 weeks (period 1: 24 weeks + period 2: 24 weeks) and 0.75 mg/kg/d of prednisone and placebo for the first 24 weeks (before crossover). Efficacy was evaluated through gross motor outcomes and safety through adverse events, growth velocity, body mass index (BMI), and bone turnover biomarkers. This analysis focused on period 2. RESULTS: A total of 121 participants with DMD were randomized. Vamorolone at a dose of 6 mg/kg/d showed maintenance of improvement for all motor outcomes to week 48 (e.g., for primary outcome, time to stand from supine [TTSTAND] velocity, week 24 least squares mean [LSM] [SE] 0.052 [0.0130] rises/s vs week 48 LSM [SE] 0.0446 [0.0138]). After 48 weeks, vamorolone at a dose of 2 mg/kg/d showed similar improvements as 6 mg/kg/d for North Star Ambulatory Assessment (NSAA) (vamorolone 6 mg/kg/d-vamorolone 2 mg/kg/d LSM [SE] 0.49 [1.14]; 95% CI -1.80 to 2.78, p = 0.67), but less improvement for other motor outcomes. The placebo to vamorolone 6 mg/kg/d group showed rapid improvements after 20 weeks of treatment approaching benefit seen with 48-week 6 mg/kg/d of vamorolone treatment for TTSTAND, time to run/walk 10 m, and NSAA. There was significant improvement in linear growth after crossover in the prednisone to vamorolone 6 mg/kg/d group, and rapid reversal of prednisone-induced decline in bone turnover biomarkers in both crossover groups. There was an increase in BMI after 24 weeks of treatment that then stabilized for both vamorolone groups. DISCUSSION: Improvements of motor outcomes seen with 6 mg/kg/d of vamorolone at 24 weeks of treatment were maintained to 48 weeks of treatment. Vamorolone at a dose of 6 mg/kg/d showed better maintenance of effect compared with vamorolone at a dose of 2 mg/kg/d for most (3/5) motor outcomes. Bone morbidities of prednisone (stunting of growth and declines in serum bone biomarkers) were reversed when treatment transitioned to vamorolone. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov Identifier: NCT03439670. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that for boys with DMD, the efficacy of vamorolone at a dose of 6 mg/kg/d was maintained over 48 weeks.

Comment In

PubMed

See more in PubMed

Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, Kunkel LM. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell. 1987;50(3):509-517. doi:10.1016/0092-8674(87)90504-6 PubMed DOI

Hoffman EP, Brown RH, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51(6):919-928. doi:10.1016/0092-8674(87)90579-4 PubMed DOI

Crisafulli S, Sultana J, Fontana A, Salvo F, Messina S, Trifirò G. Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis. Orphanet J Rare Dis. 2020;15(1):141. doi:10.1186/s13023-020-01430-8 PubMed DOI PMC

Gloss D, Moxley RT, Ashwal S, Oskoui M. Practice guideline update summary: corticosteroid treatment of Duchenne muscular dystrophy. Neurology. 2016;86(5):465-472. doi:10.1212/WNL.0000000000002337 PubMed DOI PMC

McDonald CM, Henricson EK, Abresch RT, et al. . Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. The Lancet. 2018;391(10119):451-461. doi:10.1016/S0140-6736(17)32160-8 PubMed DOI

Griggs RC, Miller JP, Greenberg CR, et al. . Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. Neurology. 2016;87(20):2123-2131. doi:10.1212/WNL.0000000000003217 PubMed DOI PMC

Guglieri M, Bushby K, McDermott MP, et al. . Effect of different corticosteroid dosing regimens on clinical outcomes in boys with Duchenne muscular dystrophy. JAMA. 2022;327(15):1456. doi:10.1001/jama.2022.4315 PubMed DOI PMC

Bello L, Gordish-Dressman H, Morgenroth LP, et al. . Prednisone/prednisolone and deflazacort regimens in the CINRG duchenne natural history study. Neurology. 2015;85(12):1048-1055. doi:10.1212/WNL.0000000000001950 PubMed DOI PMC

Griggs RC, Herr BE, Reha A, et al. . Corticosteroids in Duchenne muscular dystrophy: major variations in practice. Muscle Nerve. 2013;48(1):27-31. doi:10.1002/mus.23831 PubMed DOI

Smith EC, Conklin LS, Hoffman EP, et al. . Efficacy and safety of vamorolone in Duchenne muscular dystrophy: an 18-month interim analysis of a non-randomized open-label extension study. PLoS Med. 2020;17(9):e1003222. doi:10.1371/journal.pmed.1003222 PubMed DOI PMC

Mah JK, Clemens PR, Guglieri M, et al. . Efficacy and safety of vamorolone in Duchenne muscular dystrophy. JAMA Netw Open. 2022;5(1):e2144178. doi:10.1001/jamanetworkopen.2021.44178 PubMed DOI PMC

Guglieri M, Clemens PR, Perlman SJ, et al. . Efficacy and safety of vamorolone vs placebo and prednisone among boys with Duchenne muscular dystrophy. JAMA Neurol. 2022;79(10):1005. doi:10.1001/jamaneurol.2022.2480 PubMed DOI PMC

Reeves EKM, Hoffman EP, Nagaraju K, Damsker JM, McCall JM. VBP15: Preclinical characterization of a novel anti-inflammatory delta 9,11 steroid. Bioorg Med Chem. 2013;21(8):2241-2249. doi:10.1016/j.bmc.2013.02.009 PubMed DOI PMC

Fenton CG, Doig CL, Fareed S, et al. . 11β-HSD1 plays a critical role in trabecular bone loss associated with systemic glucocorticoid therapy. Arthritis Res Ther. 2019;21(1):188. doi:10.1186/s13075-019-1972-1 PubMed DOI PMC

Heier CR, Yu Q, Fiorillo AA, et al. . Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy. Life Sci Alliance. 2019;2(1):e201800186. doi:10.26508/lsa.201800186 PubMed DOI PMC

Hoffman EP, Riddle V, Siegler MA, et al. . Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes. Steroids. 2018;134:43-52. doi:10.1016/j.steroids.2018.02.010 PubMed DOI PMC

Conklin LS, Damsker JM, Hoffman EP, et al. . Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug. Pharmacol Res. 2018;136:140-150. doi:10.1016/j.phrs.2018.09.007 PubMed DOI PMC

Hoffman EP, Schwartz BD, Mengle-Gaw LJ, et al. . Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function. Neurology. 2019;93(13):e1312-e1323. doi:10.1212/WNL.0000000000008168 PubMed DOI PMC

R Core Team. R: A Language and Environment for Statistical Computing. R Foundation; 2022.

Wickham H. Ggplot2: Elegant Graphics for Data Analysis. Springer International Publishing; 2016. doi:10.1007/978-3-319-24277-4 DOI

Bove DS, Dedic J, Kelkhoff D, et al. . mmrm: Mixed Models for Repeated Measures. 2022. Cran.r-project.org/package=mmrm.

Chesshyre M, Ridout D, Hashimoto Y, et al. . Investigating the role of dystrophin isoform deficiency in motor function in Duchenne muscular dystrophy. J Cachexia Sarcopenia Muscle. 2022;13(2):1360-1372. doi:10.1002/jcsm.12914 PubMed DOI PMC

Hoffman EP, Clemens PR. Concerns regarding therapeutic implications of very low‐level dystrophin. Ann Neurol. 2021;90(1):176. doi:10.1002/ana.26097 PubMed DOI PMC

Feraudy Y, Ben Yaou R, Wahbi K, et al. . Very low residual dystrophin quantity is associated with milder dystrophinopathy. Ann Neurol. 2021;89(2):280-292. doi:10.1002/ana.25951 PubMed DOI PMC

Molnár Á, Kövesdi A, Szücs N, et al. . Polymorphisms of the GR and HSD11B1 genes influence body mass index and weight gain during hormone replacement treatment in patients with Addison's disease. Clin Endocrinol (Oxf). 2016;85(2):180-188. doi:10.1111/cen.13022 PubMed DOI

See more in PubMed

ClinicalTrials.gov
NCT03439670

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...